GWLLOTCFood and Kindred ProductsFiscal year ends December 31
GOLDENWELL BIOTECH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.65+0.05 (+8.33%)
Close on Oct 19, 2026
- Market cap
- $64.35M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns Goldenwell Biotech's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ming Zhou | 20,000,000 | 20.20% | 13D (active) | Oct 8, 2026 |
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Hua Xie Officer, Director, 10% Stockholder | Aug 22, 2023 | 990,000 | $247.50K | Aug 22, 2023 | Shares purchased from Issuer |